Jindrichuv Hradec, Czechia

Nada Podzimkova

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Cytune Pharma. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nada Podzimkova. Retrieved from https://idiyas.com/inventor/nada-podzimkova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nada Podzimkova: Inventor in Cancer and Infectious Disease Research

Introduction

Nada Podzimkova is an inventor associated with Jindřichův Hradec, Czech Republic. Her patent work concerns an IL-2/IL-15 receptor beta-gamma agonist dosing regimen for treating cancer or infectious diseases.

Latest Patents

The available information lists one patent associated with Podzimkova: “IL-2/IL-15R BETA GAMMA AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES.” The patent addresses dosing regimens involving an immune-signaling agonist for potential therapeutic use.

Career Highlights

Podzimkova’s reported professional affiliations include Cytune Pharma and Excoso a.s. Her listed patent reflects work related to therapeutic approaches for cancer and infectious diseases.

Collaborations

Her reported coworkers include Ulrich Moebius and David Bechard. Their names are associated with her professional and patent-related work.

Conclusion

Nada Podzimkova’s listed invention focuses on therapeutic dosing strategies, and her reported career connections include Cytune Pharma, Excoso a.s., and collaborators Ulrich Moebius and David Bechard.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…